Study S000179

Real-World Clinical Practice Study on the Effectiveness of Semaglutide Over 154 Weeks in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06983171
Study type: OBSERVATIONAL
Status: ACTIVE_NOT_RECRUITING
Enrollment: 70
Start: 2025-04-02
Primary completion: 2028-09-12
Lead sponsor: Center of target therapy
Conditions: MAFLD
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Evaluate the impact of semaglutide therapy on liver morphological changes based on liver histology using the NAFLD Activity Score (NAS). [154 weeks]
Evaluate the impact of semaglutide therapy on the degree of steatosis change based on Controlled Attenuation Parameter (CAP score) [154 weeks]
Evaluate the impact of semaglutide therapy on the degree and distribution of fat infiltration in the liver based on MR spectroscopy data [154 weeks]
Evaluate the impact of semaglutide therapy on changes in liver elasticity based on elastography data [154 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.